Longeveron Inc LGVN

US Biotechnology

$2.81 ▼ -3.44% ($-0.10)

Open $2.89

Prev Close $2.91

Day Range $2.76 – $2.95

52W Range $2.30 – $12.30

Market Cap $8.96M

Beta -0.19

EPS (TTM) $-6.72

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-02-12
Shares Out.	31,600,000
Website	longeveron.com/ ↗
Phone	13053027158
Employees	38
Revenue	$287,000
Gross Profit	$182,000
Net Income	-$6.1M
Free Cash Flow	-$20.5M
Total Assets	$15.5M
Total Liabilities	$5.1M
Equity	$10.4M

About Longeveron Inc

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Longeveron Inc is a publicly traded company under the ticker symbol LGVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.